

NET ASSET VALUE – 31 July 2025

On the 31 July 2025 Flerie AB's Net Asset Value (NAV) was SEK 4,164 million and NAV per share was SEK 53.33.

| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
|---------------------------------------|----------------------------|----------------------|--------------------------------|-----------------|
| Product Development | | | | |
| Prokarium | 42% | 453 | 5.81 | 10.9% |
| Xspray Pharma | 18% | 343 | 4.39 | 8.2% |
| Empros Pharma | 79% | 204 | 2.62 | 4.9% |
| Atrogi | 44% | 197 | 2.52 | 4.7% |
| KAHR Medical | 30% | 184 | 2.36 | 4.4% |
| Lipum | 57% | 171 | 2.19 | 4.1% |
| Xintela | 59% | 158 | 2.02 | 3.8% |
| Microbiotica | 10% | 129 | 1.65 | 3.1% |
| Mendus | 23% | 107 | 1.37 | 2.6% |
| Geneos Therapeutics | 12% | 94 | 1.20 | 2.2% |
| AnaCardio | 13% | 79 | 1.02 | 1.9% |
| Synerkine Pharma | 44% | 59 | 0.76 | 1.4% |
| EpiEndo Pharmaceuticals | 9% | 55 | 0.71 | 1.3% |
| Vitara Biomedical | 11% | 49 | 0.62 | 1.2% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.40 | 0.8% |
| Egetis Therapeutics | 1% | 31 | 0.39 | 0.7% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.7% |
| Toleranzia | 14% | 18 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.13 | 0.3% |
| Alder Therapeutics | 30% | 8 | 0.10 | 0.2% |
| Total | | 2,418 | 30.98 | 58.1% |
| Commercial Growth | | | | |
| NorthX Biologics | 61% | 202 | 2.59 | 4.8% |
| Symcel | 30% | 192 | 2.46 | 4.6% |
| Nanologica | 44% | 74 | 0.95 | 1.8% |
| Chromafora | 30% | 73 | 0.93 | 1.7% |
| Frontier Biosolutions | 2% | 18 | 0.24 | 0.4% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 43/0 | 576 | 7.38 | 13.8% |
| | | 0,7 | , , | |
| Limited Partnerships, total | | 107 | 1.37 | 2.6% |
| Assets related to Portfolio companies | | 293 | 3.75 | 7.0% |
| Other assets and liabilities | | 769 | 9.85 | 18.5% |



| Net Asset Value | 4,164 | 53.33 | 100.0 |
|-----------------|-------|-------|-------|
| | | | |

For more information:

Ted Fjällman, CEO Email: <u>ir@flerie.com</u>

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments

NET ASSET VALUE - 31 July 2025